FDG-PET study for pulmonary MAC and CPA

Evaluation of FDG-PET/CT for the disease control assessment in pulmonary Mycobacterium avium complex (MAC) infection and chronic pulmonary aspergillosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071190035

Enrollment

Registered

2019-11-15

Start date

2020-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary MAC infection, chronic pulmonary aspergillosis

Interventions

Twice FDG-PET/CT examinations (before treatment and after treatment initiation) for pulmonary MAC infection and CPA.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with pulmonary Mycobacterium avium complex (MAC) infection based on American Thoracic Society / American Society of Infectious Diseases Guideline 2017, or patients diagnosed with chronic pulmonary aspergillosis (CPA) based on the European Society of Clinical Microbiology / European Society of Medical Mycology / European Respiratory Society 2017. (2) Patients who have not been treated with antimicrobial agents against pulmonary MAC infection or CPA . (3) Patients who are older than 20 at the time of informed consent. (4) Patients with written informed consent after receiving sufficient information.

Exclusion criteria

Exclusion criteria: (1) Diabetic patients with poor control (more than 200 mg/dL of fasting blood glucose level). (2) Patients with cystic fibrosis. (3) Patients with active respiratory infection except for pulmonary MAC infection or CPA. (4) Patients with pulmonary MAC infection and CPA. (5) Patients with lung cancer at the time of informed consent. (6) Women who are currently pregnant or may be pregnant. (7) Patient who are judged unsuitable for this study by the investigator.

Design outcomes

Primary

Measure	Time frame
1. Acid-fast bacilli culture examination after 52 weeks of treatment initiation(pulmonary MAC infection) 2. Comprehensive treatment efficacy assessment after 24 weeks of treatment initiation (CPA) 3. FDG-PET/CT SUV max, SUV peak, Target/Background ratio (TBR), Metabolic Tumor Volume (MTV), Total Lesion Glycolysis (TLG)	—

Secondary

Measure	Time frame
1. Treatment efficacy after 4 and 24 weeks of treatment initiation (pulmonary MAC infection) 2. Comprehensive treatment efficacy assessment after 4 and 12 weeks of treatment initiation (CPA) 3. Restart of antimicrobial agents from 52 to 76 weeks after the first treatment start (pulmonary MAC infection) 4. Restart of antimicrobial agents from 24 to 48 weeks after the first treatment start (CPA) 5. COPD assessment test, Body weight, Serum albumin, Sputum culture examination and drug susceptibility of MAC or Aspergillus species 6. Adverse events of FDG-PET/CT examination	—

Measure

Time frame

1. Treatment efficacy after 4 and 24 weeks of treatment initiation (pulmonary MAC infection) 2. Comprehensive treatment efficacy assessment after 4 and 12 weeks of treatment initiation (CPA) 3. Restart of antimicrobial agents from 52 to 76 weeks after the first treatment start (pulmonary MAC infection) 4. Restart of antimicrobial agents from 24 to 48 weeks after the first treatment start (CPA) 5. COPD assessment test, Body weight, Serum albumin, Sputum culture examination and drug susceptibility of MAC or Aspergillus species 6. Adverse events of FDG-PET/CT examination

—

Contacts

Public ContactTakahiro Takazono

Nagasaki University Hospital

takahiro-takazono@nagasaki-u.ac.jp+81-95-819-7273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026